Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 635M 555M 512M 472M 890M 61.19B 910M 6.12B 2.41B 29.97B 2.39B 2.33B 103B P/E 2026 *
3.26x
P/E 2027 * 3.13x
Enterprise Value 635M 555M 512M 472M 890M 61.19B 910M 6.12B 2.41B 29.97B 2.39B 2.33B 103B EV / Sales 2026 *
1.38x
EV / Sales 2027 * 1.33x
Free-Float
96.84%
Yield 2026 *
-
Yield 2027 * -
1 day-0.26%
1 week-13.65%
Current month-8.31%
1 month+9.66%
3 months-12.87%
6 months-14.22%
Current year+14.54%
1 week 3.8
Extreme 3.8046
4.39
1 month 3.56
Extreme 3.565
4.88
Current year 2.95
Extreme 2.95
5.78
1 year 0.72
Extreme 0.715
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 31/03/2024
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap.
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
16/06/26 Free

Director

63,481 0.0386%
16/06/26 Free

Director

63,481 0.0386%
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%-13.65%+388.11%-62.78% 635M
-0.10%+3.21%+56.40%+20.77% 315B
-1.20%-2.43%+22.19%-8.40% 67.81B
+0.35%+2.11%+34.61%+93.22% 9.23B
+0.34%+0.51%+4.67%+0.09% 8.56B
+1.53%-3.64%-22.99%+3.93% 4.18B
-11.03%-12.07%-5.25%+15.98% 3.59B
+1.87%+3.36%-47.86%+27.51% 3.55B
-0.35%-0.87%+43.02%+63.23% 2.79B
-7.41%-2.37%+3.82%-22.47% 2.09B
Average -1.63%-3.26%+47.67%+13.11% 41.73B
Weighted average by Cap. -0.36%+0.99%+47.24%+17.00%

Financials

2026 *2027 *
Net sales 460M 402M 371M 342M 645M 44.31B 659M 4.43B 1.74B 21.7B 1.73B 1.69B 74.71B 478M 418M 386M 356M 670M 46.07B 685M 4.61B 1.81B 22.56B 1.8B 1.76B 77.67B
Net income 182M 159M 146M 135M 254M 17.49B 260M 1.75B 688M 8.57B 682M 667M 29.49B 210M 183M 169M 156M 294M 20.21B 301M 2.02B 796M 9.9B 788M 771M 34.07B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
17/07/26 US$3.860 -0.26% 1,803,987
16/07/26 US$3.870 -3.25% 2,014,530
15/07/26 US$4.000 +0.50% 1,366,536
14/07/26 US$3.980 -5.46% 2,118,770
13/07/26 US$4.210 -5.82% 2,268,681
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.860USD
Average target price
6.350USD
Spread / Average Target
+64.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock